About Biofile PDF Print E-mail

Biofile is a leading Finnish life sciences company which develops, manufactures and markets diagnostic tests.  Biofile tests support the clinical diagnosis and monitoring of autoimmune and infectious diseases, as well as Glucose and Lactose tolerance testing.  Our R&D production and clinical service laboratory operations are located in Turku, Finland.

Development and Production

Biofile products are developed using tried and tested ELISA and IFA methodologies.  Currently the product portfolio includes the Biofons Celiac Disease Panel and the Biofons Inflammatory Bowel Disease Panel.  The Celiac Disease Panel contains three tests: AGA IgA and IgG, and Endomysium IgA (hUC) IFA test.

New additions to the Biofile product range are oral solutions for Glucose and Lactose tolerance tests.

Marketing

To add extended capabilities to its product portfolio, Biofile also imports and markets diagnostic kits - mainly to the Nordic countries and the Baltic region.  In addition, distribution of all our products to other European Union countries and the Middle East is growing rapidly.

Clinical Service Laboratory

Biofile also runs a clinical service laboratory in Finland offering quality determinations of Biofile assays as well as other, rare autoimmune determinations.  For information about Biofile’s Service Laboratory, please visit our Clinical Laboratory webpages.  This section is available in Finnish only.

 
Biofons Celiac Disease Panel PDF Print E-mail

Clinical symptoms and basis of diagnostics

Coeliac disease (CD) and Dermatitis Herpetiformis (DH) are autoimmune diseases with known environmental triggers and a strong genetic component.  The external trigger is ingested wheat gluten or related proteins from rye, barley and possibly oats.  CD is a multigenic disorder with a strong HLA association.  HLA-DQ2 and DQ8 confer susceptibility together with, as yet unidentified, gene loci.  Expression of HLA-DQ2 and DQ8 molecules that present gliadin-derived peptides to CD4 T cells is necessary but not sufficient to develop CD.

Read more...